Forest Looks To Licensing, Co-Promotion And Acquiring Products Going Forward To Boost Revenue
This article was originally published in The Pink Sheet Daily
Executive Summary
Upcoming patent expiration for the firm’s top drugs, combined with a modest pipeline, prompt the need to look outside.
You may also be interested in...
Forest Once-Daily Namenda Positioned To Launch Ahead Of Immediate-Release Generics
Forest outlines top-line Phase III data showing benefit of a once-daily dose for treatment of dementia.
Forest Once-Daily Namenda Positioned To Launch Ahead Of Immediate-Release Generics
Forest outlines top-line Phase III data showing benefit of a once-daily dose for treatment of dementia.
Lexapro Pediatric Depression Filing Planned In 2008
Forest and H. Lundbeck announced Phase III study results of the SSRI in adolescents aged 12 to 17.